Dexamethasone, Cytarabine, Cisplatin and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP-cHL)
Latest Information Update: 26 Sep 2023
At a glance
- Drugs Cisplatin (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms Nivo-DHAP-cHL
Most Recent Events
- 20 Sep 2023 Status changed from recruiting to completed.
- 31 Oct 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.
- 17 Jun 2021 Preliminary results (n=20) assessing safety and efficacy of Nivo-DHAP combination as a bridge to autoHSCT in patients with R/R cHL presented at the 26th Congress of the European Haematology Association